Posted by Michael Wonder on 31 Jan 2019
Decision to open access to atomoxetine and change funded brand
31 January 2019 - PHARMAC is pleased to announce that all funding restrictions on atomoxetine will be removed from 1 July 2019.
PHARMAC will also be changing the funded brand of atomoxetine; Generic Partners’ brand will be listed from 1 July 2019; and, after a transition period the current brand Strattera will be delisted on 1 December 2019.
